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Abstract 
Background/Aims: Little is known about the effect of twice daily administration of same 
dose of ACE inhibitor and ARB on the diurnal/nocturnal blood pressure (BP) ratio. We aimed 
to assess the effect of two widely used long-acting drugs: perindopril and losartan in the 
treatment of hypertension comparing the once-daily (evening) vs. twice-daily (morning and 
evening) administration with the same daily doses. Methods: Untreated primary hypertensive 
patients without complaints (a total of 164: 65 men, 99 women, 55.7±13.7 years of age, 41-41 
patients per treated groups) were selected with non-dipper phenomenon, estimated by diurnal 
index (DI) <10%. The effect of evening (8 mg perindopril or 100 mg losartan) vs morning and 
evening (4-4 mg perindopril or 50-50 mg losartan) administration was determined on a 14-
day treatment by ABPM. Results: The mean BP, the percent time elevation index, and the 
hyperbaric impact decreased in both drug groups. Significant difference was observed in the 
DI in the case of twice-daily administration vs once-daily evening dosing. Conclusions: The 
twice-daily administration with the same daily dose of perindopril or losartan seems to be 
more effective compared to the once daily evening administration in eliminating the non-
dipper phenomenon. According to some authors the non-dipping phenomenon increases 
cardiovascular risk, while others are of the opinion that the association of non-dipping with 
cardiovascular events does not necessarily mean that selective treatment of non-dipping 
improves cardiovascular outcomes. 
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Introduction The most effective, individually tailored treatment of hypertension and the prevention of cardiovascular diseases and their complications can be achieved by the chronobiological approach, knowing the circadian rhythm. The drug’s pharmacokinetic effects and side 
effects may be modified by the circadian rhythm and the time of drug administration [1-4]. 
In the last two decades the data of 24-hour ambulatory blood pressure monitoring (ABPM) 
demonstrated that acute cardiovascular events (myocardial infarction, angina pectoris, 
cardiac arrest, sudden death, pulmonary embolism) in hypertensive patients are closely 
related to the circadian rhythm [5-9]. Diurnal rhythm is also known in the daily fluctuation 
of heart rate and blood pressure, i.e. higher diurnal, less nocturnal values. Based on 24-hour 
BP monitoring, subjects can be classified as non-dippers (nocturnal reduction of systolic 
pressure by <10 % of awake systolic pressure), dippers (reduction by ≥10 % to <20 %), 
and extreme dippers (reduction by ≥20 %). In some patients so-called “reverse dipping” 
has been described with an increase in BP during night times [1, 2, 10-13]. The dipper/
non-dipper classification of nocturnal blood pressure was firstly introduced in 1988 when 
a retrospective analysis suggested that hypertensive patients without nocturnal fall in BP 
had a higher risk of stroke than the majority of patients with a dipping pattern [1, 2, 14]. 
In non-dipper hypertension the number of cardiac events is three times more compared to 
the dipper type [5, 12, 13, 15-17]. In asymptomatic hypertensive patients who underwent 
24-hour monitoring and brain magnetic resonance imaging, the frequency of asymptomatic 
cerebrovascular damage (silent infarcts and advanced deep white matter ischemic lesions) 
was higher in non-dippers as compared to dippers, and extreme dippers had more advanced 
cerebrovascular lesions [18].Several clinical studies assessed the evening and morning administration of benazepril, 
enalapril, perindopril, quinapril, ramipril and trandolapril, confirming that if these drugs were taken in the evening, they acted more expressly on the nocturnal blood pressure, 
decreasing the non-dipping phenomenon. It was established that they more effectively decrease the diurnal blood pressure when administered in the morning and they more effectively decrease the nocturnal blood pressure when administered in the evening. Evening 
administered perindopril did not result in optimum BP control throughout 24 hours, whilst morning administration resulted in an elevated early morning peak during the critical early 
morning period. It was demonstrated by 24-hour blood pressure monitoring that significant 
blood pressure decrease occurred among non-dippers, especially in the nocturnal sleep period, and evening administration decreased the early morning rise to a greater extent 
compared to morning dosing. It can be explained by the fact that as a result of ACE inhibitor 
the diurnal/nocturnal blood pressure ratio is similar to the normal biorhythm, favourably 
influencing the circadian rhythm [19-25]. Similar observations were described in case of 
the evening administration of ARBs (valsartan, irbesartan, telmisartan, olmesartan) as well. 
Considering the circadian rhythm-dose connection, with the administration of valsartan 
the dipper status can be significantly improved and thus the cardiovascular risk can be 
decreased [25-29]. In these studies one group received the drug in the morning, the other in the evening.
Based on the above facts we can state that morning or evening administered ACE 
inhibitor or ARB did not result in optimum BP control throughout 24 hours. However, little 
is known about the effect of the twice daily administration of same doses of ACE inhibitor 
and ARB on the diurnal/nocturnal blood pressure ratio. This is the aim of our research, the 
findings of which are as follows. 
10 subjects were randomly assigned. Blockade of the RAS was evaluated with the inhibition of the pressor effect of exogenous angiotensin I, an ex vivo receptor assay, and the 
changes in plasma angiotensin II. With 200 mg OD losartan, trough blockade was 54.14%, but 
with 100 mg BID it increased to 77.8% (p<0.01) [30]. There are important data both about 
the relationship of the salinity of the diet and the effect of losartan with the intrarenal RAS 
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and the plasma thromboxane A2 level and also about the renoprotective effect of losartan. 
The effect of losartan in the change of intrarenal RAS: with Wistar rats in high-salt diet, 
Losartan failed to reduce SBP but abolished the increase of proteinuria, renal cortex renin, angiotensinogen, angiotensin II and urinary angiotensinogen when compared with high salt 
group [31]. There are similar accounts of the renal protective effect: the losartan/thiazide combination therapy attenuated glomerular overload, indicating that this therapy may 
provide glomerular protection in patients with an elevated GFR without causing prolonged 
damage to renal function [32]. With low-salt diet administering 50 mg Losartan inhibition 
of AT1 receptors could lead to activation of AT2 receptors, which maintain skin hyperaemia 
despite the increased level of vasoconstrictor thromboxane A2 [33].
Twice-daily dosing at 50-100 mg/day gave consistently larger trough responses than 
once-daily dosing at the same total dose. Peak (6 hour) effects were uniformly, but moderately, 
larger than trough effects, with the trough-to-peak ratio for systolic and diastolic responses 
50-95% and 60-90%, respectively [34]. The effects of losartan, 50 mg twice daily, were not 
significantly different from those of losartan, 100 mg once daily, but, as expected, the effects 
were greater than those of losartan, 50 mg once daily (p < .0.05) [35-37]. When once and twice daily dosing were compared, the twice daily regimen was slightly superior, but by no more 
than about 0.5 to 1 mmHg [38-40]. For this reason we aimed to assess the blood pressure 
alterations after the administration of two long-lasting drugs (ACE inhibitor: perindopril 
and ARB: losartan) in the same dose: twice-daily administration of divided dose in the 
morning and evening (4-4 mg perindopril, 50-50 mg losartan), versus once in the evening (8 
mg perindopril and 100 mg losartan) administration performing their comparative analysis, 
especially in case of hypertensive patients with non-dipper phenomenon presenting known cardiovascular risk.
Materials and Methods
The Semmelweis University Institutional Committee for Research Ethics determined that the 
proposed protocol and/or other documents adequately address relevant ethical concerns and meet 
regulatory requirements of such trials (#143/2013). Our protocol was designed in accordance with the 
ethical principles of the Declaration of Helsinki and all participants provided their written consent before entering the study.
The patients were randomly allocated to the different groups by G Ujhelyi. Numbers given to the 
patients were shuffled and randomly picked. The trial was not registered at clinicaltrials.gov due to the lack of local administrative assistance.
Inclusion criteria were: 
newly diagnosed primary hypertensive patients – total of 164 subjects, 65 men/99 women, 55.7±13.7 
(mean±SD) years of age (55.6±13.8 men, 56.2±13.2 women). Average BMI: 24± 2 men, 21±3 women were selected, with systolic blood pressure ≥160 and/or diastolic blood pressure ≥100 mmHg. The positive 
diagnosis of hypertension was confirmed by ABPM: patients with either the 24h mean systolic and diastolic 
blood pressure (SBP/DBP) above 130/80 mmHg, the diurnal mean above 135/85 mmHg or the nocturnal 
mean above 120/70 mmHg untreated were considered as hypertensive. Moreover, inclusion criteria 
required all patients to be non-dipper (here defined as <10% decline in nocturnal mean compared with the 
diurnal mean of SBP using all data sampled by ABPM for 24 consecutive hours). 
•	 not taking any other medicine regularly 
•	 ejection fraction with echocardiography method: 
•	 left ventricle hypertrophy, valve disorders
•	 no cardiologic complaints
•	 normal sleep quality with normal daily activities
•	 clinically free of any sleep-related disorder
•	 Caucasian 
•	 having a sedentary occupation 
•	 BMI <35 
•	 non-smoker 
•	 not consuming alcohol or drugs 
•	 having no other comorbidity 
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Exclusion criteria were:
•	 cardiopulmonary disease
•	 metabolic disorder
•	 endocrine disorders
•	 other comorbidities 
•	 inefficient compliance 
•	 drug consumption
•	 drug side effect
•	 sleep disorders 
•	 smoking habits
•	 alcohol consumption
•	 drug consumption
•	 anabolic steroid consumption
•	 patients whose blood pressure was normalized after one dose of drug 
During 24 hours ABPM each participant wore an „Aktigraf” (motion-logger actigraph, Meditech 
Ltd, Budapest, Hungary) on the dominant wrist to monitor physical activity every minute. This compact 
(about the size of a wrist watch) device functions as an accelerometer. The internal clocks of the actigraph 
and the ABPM devices were synchronized through their respective interfaces by the same computer. The actigraphy data were used to determine the onset and offset times of diurnal activity and nocturnal sleep so 
as to accurately determine the diurnal and nocturnal BP means of each subject. The mean activity for the 5 
minutes before each BP reading was then calculated for further statistical analysis [41].
24-hour ambulatory blood pressure monitoring was performed with “ABPM-05” device (Meditech 
Ltd, Budapest, Hungary). Measuring methods were: oscillometric method, staged pressure lowering, 
semiconductor pressure sensor. Measuring range: 30-260 mmHg, heart rate 40-200/min. Passive accuracy: 
±3 mmHg or 2% of the measuring value. Data transfer with USB optical cable. The software of the device 
enables all-round data analysis: mean blood pressure, percent time elevation index (PTEI), hyperbaric 
impact, diurnal index (DI). The measuring accuracy of ABPM-05 device algorithm was ensured by British 
Hypertension Society (BHS) and by Association for the Advancement of Medical Instrumentation (AAMI) validations. 
The 24-hour ambulatory blood pressure monitor was programmed for measurements every 20 
minutes during the day and every 30 minutes during the night. Day period was considered the period from 
6 a.m. to 10 p.m., night period was considered from 10 p.m. to 6 a.m. The patient wrote a detailed log-book about the activities. In case of complaints the patient could initiate blood pressure measurement apart from the programmed ones at any time, or could give a sign when reading the measurement data of the device.
In all three studies we measured:
•	 Systolic and diastolic mean values (mmHg)
•	 Systolic and diastolic hypertensive time index in % 
Hypertensive Time Index, or percent time elevation index (PTEI) is the proportion of time during which blood pressure values are higher than what is considered to be normal. The hypertension time index 
compares the period with elevated blood pressure to total time. Value above 15% refers to hypertension, 
value above 40% may refer to target organ lesion [1, 2, 14]. 
•	 Systolic and diastolic diurnal index in % (DI)
Diurnal or day / night index is the difference between day-time and night-time blood pressure 
expressed in percent (daytime value averages divided by the night-time average and multiplied by 100). 
<10% systolic or diastolic value refers to non-dipper phenomenon, and it may indicate target organ damage, 
diabetes or non-efficient antihypertensive drug treatment as well. >20% diurnal index refers to extreme 
dipping [1, 2, 14].
•	 Systolic and diastolic hyperbaric impact or pressure load: in mmHg x h 
Hyperbaric impact or hypertension load provides information on how long blood pressure is higher than normal and how much it is higher than the upper limit of normal ambulatory blood pressure during 
ABPM monitoring. It expresses the over ranged blood pressure not only in time, but its extent in mmHg x 
hour unit. It expresses most accurately the extent of hypertension for the examined period [1, 2, 14]. 
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evening times of the drug administration were adjusted (8 a.m. and 8 p.m.) on their cell phones and warning 
messages were sent daily to which the patients forwarded a confirmative feedback if the drug application was performed successfully. 
Treatment design:
Study I: drug-free, basic 24-hour blood pressure monitoring (ABPM) 
  164 patients 65 men, 99 women 
Study II: group 1: 8 mg perindopril at 8 p.m.
  41 patients (16 men, 25 women)   group 2: 100 mg losartan at 8 p.m.
41 patients (16 men, 25 women)
ABPM after 14 days from first administration
Study III: group 1: 4 mg perindopril at 8 a.m., 4 mg perindopril at 8 p.m.
  41 patients (16 men, 24 women)  group 2: 50 mg losartan at 8 a.m., 50 mg losartan at 8 p.m.
  41 patients (17 men, 25 women)
  ABPM after 14 days from first administration
  (group 1: treatment with perindopril, group 2: treatment with losartan)
In the first week of the study the patients conducted home blood pressure monitoring three times 
a day (recumbent after waking up, between 11-12 a.m., between 7-8 p.m.) If their blood pressure did not 
decrease below 160/100 Hgmm after the first week, as co-medication females got 5 mg of amlodipine. These patients were excluded from further study. 
Statistical analysis
For statistical evaluation R 2.11.1 software package (2010) was applied. Differences between means 
were evaluated by one-way analysis of variance (one-way ANOVA) with post-hoc Tukey test, if data were of 
normal distribution and homogeneity of variances was confirmed or Kruskal-Wallis nonparametric test. A p 
value of <0.05 was accepted to indicate statistical significance.
Results
There was no significant difference except for the diurnal index in the effect of once-
daily (evening) vs twice-daily perindopril and losartan administration (Table 1).
The 24-hour mean systolic values became significantly lower in both the once-daily and 
the twice-daily administration groups while the diastolic values decreased moderately but 
not significantly (Figure 1).
Diurnal main systolic values became significantly lower in both the once-daily and 
the twice-daily administered perindopril and losartan groups while the diastolic values 
decreased moderately but not significantly.
Night time mean systolic values became significantly lower in both the once daily and the twice daily administered perindopril and losartan groups while the diastolic values 
decreased moderately but not significantly.
Diurnal blood pressure control was not optimal in either drug groups regardless of 
dosage. However with once-daily administration the night time mean values were higher 
while they decreased with twice-daily dosage. This can explain the more favourable diurnal index in the case of the twice daily dosage.
The percent time elevation index (PTEI) and the hyperbaric impact notably decreased, 
but not significantly in both drug groups in case of evening and twice-daily administration 
(Figure 2 and 3).
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Table 1. Study results
Fig. 1. Mean systolic and di-astolic values are expressed 
in mmHg in control and in losartan or per-
indopril-treat-
ed groups. No 
significant dif-ferences were found between groups treat-ed once daily or twice daily with perin-
dopril (group 
1) and losar-
tan (group 2) 
(p>0.05, n=41).
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Diurnal index increased non-significantly in case of once-daily administration with both 
drugs, however, it showed significant (p<0.05) increase during twice-daily administration 
both with of losartan and perindopril. 10% or above of diurnal index indicated the cessation 
of non-dipper phenomenon (Figure 4).
Comparing the effect of perindopril and losartan: there was no significant difference 
either in the once-daily or in twice-daily administration group, both drugs moderated the 
mean blood pressure, PTEI and hyperbaric impact in a similar rate.
Fig. 2. Systolic and diastolic hy-pertension time 
index (PTEI) val-ues in control and in losartan or 
perindopril-treat-ed groups are 
described. No 
significant differ-ences were found between groups treated once dai-ly or twice daily with perindopril 
(group 1) and lo-
sartan (group 2) 
(p>0.05, n=41).
Fig. 3. Hyperbar-ic impact values are expressed in 
mmHg x h. No 
significant differ-ences were found between groups treated once dai-ly or twice daily with perindopril 
(group 1) and lo-
sartan (group 2) 
(p>0.05, n=41).
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Discussion
The therapeutic range and efficiency of various antihypertensive drugs significantly 
depends on their circadian rhythm administration. In hypertension, knowing the frequency 
of abnormal rise of blood pressure in the morning and night-time, chronotherapy should be applied to reduce the morning rise to a normal level, but also to ensure a favourably 
influence on the night-time non-dipping period. 
Chronotherapy, considering the patients’ circadian blood pressure profile, gives scope for the individualized treatment of hypertension, the attainment of optimal blood pressure control and it decreases the risk of cardiovascular diseases and organ lesions. It 
is known that the evening administration of ACE inhibitors and ARBs resulted in improved 
diurnal/nocturnal blood pressure ratio (increase of diurnal index), as opposed to morning administration. 
Clinical studies have documented that evening administration of ACE inhibitors and 
ARBs resulted in improved diurnal/nocturnal blood pressure ratio, as opposed to morning administration, however, less is known about the effect of the twice daily administration 
of the same doses of ACE and ARB on the diurnal/nocturnal blood pressure ratio. The 
effect of the two most widely used long-acting antihypertensive ACE inhibitor and ARB 
drugs: perindopril and losartan in the treatment of hypertension comparing the once-daily 
administration (evening) to the twice-daily (morning and evening) administration in the 
same dose with 24-hour blood pressure monitoring (ABPM) has been investigated by us.
The once-daily (evening) dose of perindopril (8 mg) and losartan (100 mg) and the 
twice daily administration (morning and evening 4-4 mg perindopril and 50-50 mg losartan) 
did not significantly decrease the mean blood pressure, the PTEI and the hyperbaric impact. 
In twice-daily administration the difference between diurnal and nocturnal blood 
pressure value, expressed in the percent of daytime value (diurnal index), significantly 
increased compared to the once-daily evening administration. Based on the study, in 
Fig. 4. Diurnal index values are expressed in %. There were significant differences between groups treated 
once daily or twice daily with perindopril (group 1) and losartan (group 2) (*p<0.05, n=41).
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the treatment of non-dipper hypertension the twice-daily administration of same dose 
of perindopril and the same dose of losartan seems to be more favourable to cease non-
dipper phenomenon than the once-daily evening administration. There is no common understanding regarding cardiovascular events and cardiovascular risks accompanying the 
non-dipper phenomenon. According to some authors non-dipping increases cardiovascular 
risk [5, 12, 13, 15-17, 42-46] while others are of the opinion that the association of non-dipping with cardiovascular events does not necessarily mean that selective treatment of 
non-dipping improves cardiovascular outcomes. This is explained by the fact that factors 
other than the non-dipping phenomenon have stronger influence on cardiovascular risk. These factors include age, smoking, inactive way of life, comorbidities like obesity, diabetes 
mellitus, lipid metabolic disorder [47-54].
Although we did not observe extreme dipping phenomenon i.e. aggressive blood pressure lowering during night time in the course of our study, it is important to mention that aggressive blood pressure lowering during night time in itself can be the risk factor of cardiovascular diseases like ischaemic stroke or nephropathy and it causes nocturnal 
ischaemia more often than the non-dipper phenomenon. The risk for the primary end points 
- death and MI, but not stroke - progressively increased with low diastolic blood pressure. 
Excessive reduction in diastolic pressure should be avoided in patients with CAD who are being treated for hypertension.
While average night time to daytime BP ratio <0.80 has been defined as “extreme 
dipping,” and in at least a couple of studies it has been associated with an increased risk 
of cerebrovascular disease in older adults, a large meta-analysis examining the prognostic 
significance of night time BP patterns found no difference between dippers and extreme 
dippers in the rate of cardiovascular events. Among treated hypertensive patients with CAD, 
nocturnal ischemia was shown to be significantly more frequent in over-dippers than in 
dippers and non-dippers [55-66]. 
Conclusion
The study confirmed the previously known fact that ACE inhibitors or ARBs (in the 
present study: perindopril and losartan) are not sufficient alone in monotherapy to ensure 
the appropriate target value (normotension).
Limitations
The dipping/non-dipping pattern is usually defined on the basis of a single ABPM; this 
classification, however, may not reflect a true clinical trait. Indeed, a large amount of evidence 
indicates that classification of dippers and non-dippers has a limited reproducibility. This is 
mostly due to the fact that sleep quality and depth during night-time can markedly vary from 
one recording session to another [3, 27].
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